{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["88(10)"],"submitter":["Klein S"],"pubmed_abstract":["<h4>Aims</h4>Neuronal hypersensitisation due to adenosine triphosphate-dependent P2X3 receptor signalling plays a significant role in several disorders including chronic cough and endometriosis. This first-in-human study of eliapixant (BAY 1817080) investigated the tolerability, safety and pharmacokinetics (PK) of single doses of eliapixant, including the effect of food and coadministration with a CYP3A inhibitor on eliapixant relative bioavailability.<h4>Methods</h4>In this randomised, double-blind phase I study (NCT02817100), 88 healthy male subjects received single ascending doses of immediate-release eliapixant (10-800 mg) tablets or placebo under fasted conditions, with food (low-fat continental or high-fat American breakfast) or with itraconazole (fasted state). PK parameters, dose p"],"journal":["British journal of clinical pharmacology"],"pagination":["4552-4564"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9546310"],"repository":["biostudies-literature"],"pubmed_title":["First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics."],"pmcid":["PMC9546310"],"pubmed_authors":["Klein S","Hummel T","Baumann S","Friedrich C","Gashaw I","Thuß U","Chang X"],"additional_accession":[]},"is_claimable":false,"name":"First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.","description":"<h4>Aims</h4>Neuronal hypersensitisation due to adenosine triphosphate-dependent P2X3 receptor signalling plays a significant role in several disorders including chronic cough and endometriosis. This first-in-human study of eliapixant (BAY 1817080) investigated the tolerability, safety and pharmacokinetics (PK) of single doses of eliapixant, including the effect of food and coadministration with a CYP3A inhibitor on eliapixant relative bioavailability.<h4>Methods</h4>In this randomised, double-blind phase I study (NCT02817100), 88 healthy male subjects received single ascending doses of immediate-release eliapixant (10-800 mg) tablets or placebo under fasted conditions, with food (low-fat continental or high-fat American breakfast) or with itraconazole (fasted state). PK parameters, dose p","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-22T01:52:50.955Z","creation":"2025-04-05T20:10:22.502Z"},"accession":"S-EPMC9546310","cross_references":{"pubmed":["35437837"],"doi":["10.1111/bcp.15358"]}}